Annual report pursuant to Section 13 and 15(d)

CONDENSED BALANCE SHEETS

v3.22.1
CONDENSED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 6,037 $ 5,413
Restricted cash 295 0
Receivables 112 884
Inventory 293 328
Prepaid expenses and other current assets 480 522
Discontinued operations - current assets 12 181
Total current assets 7,229 7,328
Property and equipment, net 420 618
Other assets 48 0
Operating lease right-of-use asset 297 141
Total assets 7,994 8,087
Current liabilities:    
Accounts payable 795 1,253
Accrued clinical trials expenses 9 214
Other accrued liabilities 314 319
Operating lease liability, current 112 150
Current portion of long-term debt 0 327
Deferred grant revenue 295 0
Discontinued operations - current liabilities 1,144 1,960
Total current liabilities 2,669 4,223
Long-term debt, net 0 332
Operating lease liability, non-current 187 0
Total liabilities 2,856 4,555
Commitments and contingencies (Note 5)
Stockholders' equity:    
Preferred stock, $0.001 par value per share; 5,000,000 shares authorized, none issued or outstanding at December 31, 2021 and 2020. 0 0
Common stock, at amounts paid-in, $0.001 par value per share; 225,000,000 shares authorized 9,914,158 and 7,139,068 shares issued and outstanding at December 31, 2021 and 2020, respectively. 10 7
Additional paid-in capital 381,183 370,804
Accumulated deficit (376,055) (367,279)
Total stockholders' equity 5,138 3,532
Total liabilities and stockholders' equity $ 7,994 $ 8,087